As TRAIL-R1 and TRAIL-R2 are apoptosis triggers that are active specifically in cancer cells rather than healthy cells (31, 32), TRAIL-based therapies have become potential cancer targeting strategies. The gene discussed is TNFRSF10A; the disease is cancer.